Because autoimmune disorders can wreak havoc in both humans and animals, these disorders are now the objects of intense and focused research. This book details specific animal models for a variety of autoimmune disorders. The contributors are recognized authorities who deal with the panoply of experimentally induced autoimmune disorders, including encephalomyelitis, allergic neuritis, uveoretinitis, myocarditis, and hepatitis. Also included are discussions of spontaneously appearing diseases such as autoimmune thyroiditis and systemic lupus erythematosus. Many other disorders are also covered in this comprehensive guide. Certain to be an aid in the planning of individual experiments and broader research programs, this book will be a valuable addition to the library of all practicing immunologists interested in immune system function and dysfunction.
Inhaltsverzeichnis
1;Front Cover;1 2;Autoimmune Disease Models: A Guidebook;4 3;Copyright Page;5 4;Table of Contents;6 5;Contributors;14 6;Preface;18 7;Chapter 1. Experimental Autoimmune Encephalomyelitis in the Mouse;20 7.1;I. Introduction: Murine Experimental Autoimmune Encephalomyelitis as a Model for T-CelI-Mediated Demyelinating Disease of the Central Nervous System;20 7.2;II. Models of EAE in the Mouse;21 7.3;III. Evaluation of the Disease;25 7.4;IV. Summary;31 7.5;Acknowledgment;32 7.6;References;32 8;Chapter 2. Rat Experimental Autoimmune Encephalomyelitis;34 8.1;I. History and Introduction;34 8.2;II. Animals and Housing;35 8.3;III. Genetic Background;35 8.4;IV. Disease Induction;36 8.5;V. Quantitation;38 8.6;VI. Expert Experience;39 8.7;References;40 9;Chapter 3. Theiler's Virus-Induced Demyelinating Disease;42 9.1;I. History and Relevance of the Model;42 9.2;II. The Animals;44 9.3;III. Genetics of Susceptibility or Resistance;44 9.4;IV. The Disease;46 9.5;V. Lessons;55 9.6;References;55 10;Chapter 4. Experimental Autoimmune Neuritis;58 10.1;I. Introduction;58 10.2;II. Isolation and Composition of Peripheral Nerve Myelin;59 10.3;III. Basic Features of EAN;60 10.4;IV. Immunopathogenesis of EANA Model for Therapeutic Studies;71 10.5;References;72 11;Chapter 5. Experimental Autoimmune UveoretinitisRat and Mouse;76 11.1;I. Introduction;76 11.2;II. Rat EAU;79 11.3;III. Mouse EAU;87 11.4;IV. Expert Experience;94 11.5;V. Lessons;96 11.6;References;96 12;Chapter 6. Experimental Autoimmune Myasthenia Gravis;102 12.1;I. Introduction;102 12.2;II. Immunization against Purified Electric Organ AChR;104 12.3;III. Assessment of EAMG and the Safety Factor;108 12.4;IV. Immunization against Purified Mammalian AChR;109 12.5;V. Immunization without Adjuvant;109 12.6;VI. Genetics of EAMG in Rats and Mice;111 12.7;VII. T- and B-Cell Epitopes in EAMG;114 12.8;VIII. Immunization against Denatured AChR Subunits, Recombinant or Synthetic Peptides;116 12.9;IX. Resistance to EAMG;116 12.10;X. Alternative
Models;118 12.11;XI. Use of EAMG for Therapeutic Studies;120 12.12;XII. Relation to Human Disease;120 12.13;XIII. Conclusions;120 12.14;XIV. Lambert-Eaton Myasthenic Syndrome;122 12.15;References;122 13;Chapter 7. The Obese Strain of Chickens with Spontaneous Autoimmune Thyroiditis as a Model for Hashimoto Disease;126 13.1;I. Introduction;126 13.2;II. History and Development of the OS;127 13.3;III. Clinical Symptoms and Pathohistology;128 13.4;IV. Immunological Parameters;129 13.5;V. Breeding and Management of OS Chickens;135 13.6;VI. Immunogenetics;137 13.7;VII. Comparison of SAT and EAT;138 13.8;VIII. Use of the OS for the Development of New Therapeutic Strategies;139 13.9;IX. Conclusions;140 13.10;Acknowledgments;140 13.11;References;140 14;Chapter 8. Experimental Autoimmune Thyroiditis in the Mouse and Rat;142 14.1;I. Experimental Autoimmune Thyroiditis in the Mouse;142 14.2;II. Experimental Autoimmune Thyroiditis in the Rat;152 14.3;III. Lessons;157 14.4;Acknowledgments;161 14.5;References;161 15;Chapter 9. The NOD Mouse: A Model for Autoimmune Insulin-Dependent Diabetes;166 15.1;I. History of the Model;166 15.2;II. The Animal;167 15.3;III. The Disease;168 15.4;IV. Genetics;173 15.5;V. Treatment and Prevention;175 15.6;VI. Notes for the Beginner;177 15.7;VII. What the Model Has Taught Us about Human IDDM;178 15.8;References;178 16;Chapter 10. The BB Rat Models of IDDM;182 16.1;I. History;182 16.2;II. Animals;182 16.3;III. Genetics;185 16.4;IV. The Disease;186 16.5;IV. Quantitation;190 16.6;V. Resistance;190 16.7;VI. Expert Experience;191 16.8;VII. Lessons;191 16.9;References;192 17;Chapter 11. Experimental Myocarditis;194 17.1;I. The Models;194 17.2;II. Production of Virus-Induced Myocarditis;196 17.3;III. Production of Myosin-lnduced Myocarditis;200 17.4;IV. Evaluation;201 17.5;Acknowledgment;207 17.6;References;207 18;Chapter 12. Experimental Hepatitis;210 18.1;I. History of Experimental Autoimmune Hepatitis;210 18.2;II. Animals;212 18.3;III. Genetic Backgro
und;212 18.4;IV. Induction and Time Course;212 18.5;V. Quantitation;215 18.6;VI. Resistance;216 18.7;VII. Expert Experience;216 18.8;VIII. Lessons;217 18.9;References;217 19;Chapter 13. Adjuvant Arthritis;220 19.1;I. History of the Model;220 19.2;II. Animals;221 19.3;III. Induction of the Disease;222 19.4;IV. Course of the Disease;227 19.5;V. Quantitation of the Disease;228 19.6;VI. Resistance to the Disease;230 19.7;VII. Expert Experience;231 19.8;VIII. Lessons;232 19.9;Acknowledgment;233 19.10;References;233 20;Chapter 14. Murine Models of Spontaneous Systemic Lupus Erythematosus;236 20.1;I. Introduction;236 20.2;II. (NZB x NZW) F;237 20.3;III. MRL-lpr/lpr;244 20.4;IV. Quantitation;255 20.5;V. Conclusions;259 20.6;Acknowledgment;259 20.7;References;259 21;Chapter 15. Experimental Systemic Lupus Erythematosus: Role of the Idiotypic Network;264 21.1;I. History of the Model;264 21.2;II. Animals and Housing;266 21.3;III. Genetic Background;267 21.4;IV. Disease Induction;268 21.5;V. Course of the Disease;269 21.6;VI. Resistance to the Disease;270 21.7;VII. Manipulation of the Disease;271 21.8;VIII. Lessons;272 21.9;Acknowledgment;272 21.10;References;272 22;Chapter 16. Autoimmune Vasculitis;276 22.1;I. Introduction and History of the Model;276 22.2;II. Animals;276 22.3;III. Genetic Background;277 22.4;IV. Disease Induction;277 22.5;V. Lesion and Course of the Disease;278 22.6;VI. Autoimmune Myositis;283 22.7;References;283 23;Chapter 17. Testicular and Ovarian Autoimmune Diseases;286 23.1;I. Introduction;286 23.2;II. Experimental Autoimmune Orchitis;287 23.3;III. Experimental Autoimmune Oophoritis;294 23.4;IV. Autoimmune Oophoritis Following Manipulation of the Normal Murine Immune System;299 23.5;V. Summary and Conclusions;306 23.6;Acknowledgments;307 23.7;References;307 24;Chapter 18. Allogeneic Diseases;310 24.1;I. Chronic Graft-versus-Host Disease;310 24.2;II. Host-versus-Graft Disease;314 24.3;III. Lessons;318 24.4;References;319 25;Chapter 19. Assessment of Disco
mfort in Laboratory Animals;322 25.1;I. Introduction;322 25.2;II. Arguments for Assessing Discomfort;323 25.3;III. Stress and Discomfort;324 25.4;IV. Assessment of Discomfort;330 25.5;V. An Example of Assessing Discomfort in Practice;333 25.6;VI. Possibilities for Diminishing Discomfort;335 25.7;References;337 26;Index;340